Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176040 | 1.00 | S1PR1 (0.54) | S1PR1S1PR3 | |
| SCHEMBL1174770 | 0.83 | S1PR1 (0.59) | S1PR1S1PR3 | |
| SCHEMBL1174771 | 0.83 | S1PR1 (0.59) | S1PR1S1PR3 | |
| SCHEMBL1174767 | 0.83 | S1PR1 (0.59) | S1PR1S1PR3 | |
| SCHEMBL1175396 | 0.80 | TSHR (0.49) | S1PR1S1PR3 | |
| SCHEMBL1175393 | 0.80 | TSHR (0.49) | S1PR1S1PR3 | |
| SCHEMBL3086420 | 0.79 | S1PR1 (0.58) | S1PR1S1PR3 | |
| SCHEMBL1174844 | 0.79 | S1PR1 (0.58) | S1PR1S1PR3 | |
| SCHEMBL3092062 | 0.79 | S1PR1 (0.58) | S1PR1S1PR3 | |
| SCHEMBL1174762 | 0.78 | S1PR1 (0.54) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970236-B1 | PYRIDIN-4-YL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-30 | — | — | EP | disclosed |
| US-9617250-B2 | Pyridin-4-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-04-11 | — | — | US | disclosed |
| US-20160031866-A1 | PYRIDIN-4-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-04 | — | — | US | disclosed |
| EP-2970236-A1 | PYRIDIN-4-YL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014141171-A1 | PYRIDIN-4-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-8658675-B2 | Pyridin-4-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-25 | — | — | US | disclosed |
| EP-2217594-B1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2454255-B1 | PYRIDIN-4-YL DERIVATIVES AS S1P1/EDG1 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-8575200-B2 | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-05 | — | — | US | disclosed |
| EP-2252609-B1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-17 | — | — | EP | disclosed |
| EP-2252609-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-16 | — | — | US | disclosed |
| EP-2222667-A2 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-01 | — | — | EP | disclosed |
| EP-2217594-A2 | NOVEL PYRIMIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009109872-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109906-A1 | PYRIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109904-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009074950-A2 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009057079-A2 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031866-A1 | PYRIDIN-4-YL DERIVATIVES | CD4, IL2, CD47 | S1PR1 64/4885S1PR3 108/4885 |
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR3 2/4885 |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | S1PR1 989/4885S1PR3 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.